U.S., June 11 -- ClinicalTrials.gov registry received information related to the study (NCT07011823) titled 'Immune-checkpoint Blockade After Partial Breast Irradiation by Pembrolizumab in Early TNBC' on June 02.
Brief Summary: A single-arm, single-institution study to induce phenotypic changes in the tumor microenvironment by delivering 8Gy partial breast irradiation in immune-cold triple-negative breast cancer confirmed by PD-L1 and TILs. Additional tissue biopsy will be performed following radiation therapy. Subsequently, neoadjuvant chemotherapy including Pembrolizumab will be administered to evaluate whether pathological complete response rates are improved.
Study Start Date: July 16
Study Type: INTERVENTIONAL
Condition:
Triple-Ne...